Imunon director receives 10,330-share stock award

Fritz Frederick J. reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Fritz Frederick J. reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc. director Frederick J. Fritz received an equity grant of 10,330 shares of Common Stock at $2.20 per share. The Form 4 describes this as a grant or award, not an open-market purchase. After this transaction, he directly owns 14,097 Imunon shares.

According to the accompanying footnote, the stock was granted in lieu of cash for a portion of his board fees, making this a compensation-related award rather than a discretionary share purchase in the market.

Insights

Equity compensation analyst

Director received routine stock compensation instead of cash fees.

Director Frederick J. Fritz was granted 10,330 Imunon Common Stock shares at $2.20 per share as compensation, classified as a “Grant, award, or other acquisition.” The grant increased his direct holdings to 14,097 shares.

The footnote states the stock was granted in lieu of cash for a portion of board fees, indicating a standard equity-based compensation choice rather than an open-market signal trade. This type of transaction is generally viewed as routine and primarily affects how the director is paid, not the company’s fundamentals.

Insider Trade Summary

Grant/Award: 10,330 shares

Grant/Award 1 txn

Insider Fritz Frederick J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	10,330	$2.20	$23K

Holdings After Transaction: Common Stock — 14,097 shares (Direct)

Footnotes (1)

1. F1. Stock granted in lieu of cash for portion of board fees.

Key Figures

Shares granted: 10,330 shares Grant price per share: $2.20 per share Shares owned after transaction: 14,097 shares +1 more

4 metrics

Shares granted 10,330 shares Common Stock grant on May 22, 2026

Grant price per share $2.20 per share Valuation used for the 10,330-share award

Shares owned after transaction 14,097 shares Director’s direct holdings following the grant

Transaction type Grant, award, or other acquisition Form 4 transaction code A classification

Key Terms

Grant, award, or other acquisition, Common Stock, in lieu of cash, Form 4

4 terms

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

in lieu of cash financial

"Stock granted in lieu of cash for portion of board fees."

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Imunon (IMNN) director Frederick J. Fritz report on this Form 4?

Director Frederick J. Fritz reported receiving a grant of 10,330 shares of Imunon Common Stock at $2.20 per share. This award increased his direct ownership to 14,097 shares and is classified as a grant, award, or other acquisition rather than a market trade.

Was the Imunon (IMNN) Form 4 transaction an open-market stock purchase?

No, the transaction was not an open-market purchase. The Form 4 classifies it as a grant or award, and a footnote explains the stock was granted in lieu of cash for a portion of board fees, indicating routine equity compensation, not discretionary buying in the market.

How many Imunon (IMNN) shares does Frederick J. Fritz own after this grant?

After the grant, Frederick J. Fritz directly owns 14,097 shares of Imunon Common Stock. This total includes the 10,330-share award reported in the transaction, which was granted as part of his compensation for serving on the company’s board of directors.

What price per share was used for the Imunon (IMNN) stock grant on the Form 4?

The stock grant to director Frederick J. Fritz was valued at $2.20 per share. This price is disclosed as the transaction price per share for the 10,330-share award, which was issued as stock in lieu of a portion of his board fee compensation.

Why did Imunon (IMNN) grant stock to its director instead of paying full cash fees?

A footnote explains the 10,330 Imunon shares were granted in lieu of cash for part of director Frederick J. Fritz’s board fees. This indicates the company used equity-based compensation, a common practice to align director interests with shareholders and conserve some cash outlays.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/27/2026 - 04:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fritz Frederick J.

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/22/2026		A		10,330(1)	A	$2.2	14,097	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for portion of board fees.

Remarks:

On August 21, 2025, the Issuer paid a 15% stock dividend, 0.15 shares of common stock per share of the Issuer's issued and outstanding shares of common stock, to stockholders of record as of August 7, 2025. As a result of the stock dividend, the shares of Issuer Common Stock have been adjusted accordingly versus any amounts previously reported by the Reporting Person.

	/s/ Susan Eylward, Attorney-in-Fact for Frederick J. Fritz	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)